U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period should target newer strains of the JN.1 variant. COVID vaccine makers are ...

The mRNA vaccines were developed using novel technology that was approved for the first time for public use during the COVID-19 pandemic.